ABSTRACT
The chapter has comprehensively focused on some very unknown natural chalcone compounds (kuwanon J, kuwanon R, kuwanon V, isoliquiritigenin, xanthoangelol, xanthoangelol D, xanthoangelol E, xanthoangelol F, xanthoangelol K, 4-hydroxyderricin, 5,4’-dihydroxy-6,7-furanbavachalcone, licochalcone A, licochalcone B, licochalcone C, licochalcone D, licochalcone E, echinatin, laxichal-cone, broussochalcone, macdentichalcone, (2E)-1-(5,7-dihydroxy-2,2-dimethyl-2H-benzopyran-8-yl)-3-phenyl-2-propen-1-one, (2E)-1-(5,7-dihydroxy-2,2,6-trimethyl-2H-benzopyran-8-yl)-3-(4-methoxyphenyl)-2-propen-1-one, and abyssinone-VI-4-O-methyl ether) having tremendous potential to exhibit antidiabetic activity 90by selectively modulating the promising therapeutic target protein tyrosine phosphatase 1B (PTP-1B) that will prevent the degradation of insulin. In modern days, these natural product chalcone-based PTP-1B inhibitors are not under clinical use and they have not received any such attention in modern-day medicine as they are not explored clinically in terms of toxicological profiles to develop a suitable formulation. In the near future, it is expected that these chalcone-based PTP-1B inhibitors will open new avenues of diabetotherapeutics.
